Chris York joined SLR Capital Partners as a partner. York will focus on product and business development, leveraging his 17 years of experience in the credit and alternatives investment industry.
Ingrid Kiefer will join SLR Capital Partners this month as a partner and chief business development officer. Kiefer will lead SLR’s business development and investor relations, leveraging more than 25 years of experience in the credit and alternative investment industry.
Alimera Sciences amended and extended its $45 million term loan agreement with SLR Capital Partners to extend the interest-only period for at least two years and extend the final maturity date to April 30, 2028.
SLR Capital Partners, a boutique asset manager, closed on $2.2 billion of equity commitments within SLR’s direct cash flow lending and specialty finance strategies during the second half of 2022.
Outset Medical entered into two senior secured credit facilities with investment affiliates managed by SLR Capital Partners, which collectively provide for borrowings of up to $300 million, comprising up to a $250 million term loan facility and up to a $50 million asset-based revolving credit facility.
Spectrum Pharmaceuticals, a biopharmaceutical company focused on novel and targeted oncology therapies, entered into a five-year debt financing agreement with investment affiliates managed by SLR Capital Partners for a term loan facility of up to $65 million.
SLR Investment Corp. closed its previously announced merger with SLR Senior Investment Corp., with SLR Investment Corp. as the surviving company.
Arcutis Biotherapeutics, a late-stage biopharmaceutical company focused on developing innovations in immuno-dermatology, obtained a $225 million term loan facility from funds managed by SLR Capital Partners.
SLR Investment Corp. (SLRC) and SLR Senior Investment Corp. (SUNS) entered into an agreement to merge together, with SLRC as the surviving company, subject to stockholder approval and customary closing conditions.